The financials
Pfizer by the numbers
Pfizer (PFE) reported revenue of $15.0B in Q2 2026 (quarter ended June 28, 2026), up 2.6% from the same quarter a year earlier. That came with a gross margin of 73% and net loss of $248M. For the full year FY2025, revenue was $62.6B (−1.6% year on year) and net income $7.77B. Its largest product in 2026-Q1 was Eliquis at $2.17B, 15% of the disclosed total, just ahead of Prevnar Prevenar Family at 11%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $15.0B | $14.7B | +2.6% |
| Gross profit | $10.9B | $10.9B | +0.6% |
| Net income | −$248M | $2.91B | to a loss |
| Diluted EPS | −$0.04 | $0.51 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Eliquis | $2.17B | 15% |
| Prevnar Prevenar Family | $1.69B | 11% |
| Vyndaqel | $1.60B | 11% |
| Ibrance | $1.01B | 6.8% |
| All Other Hospital And Biosimilars | $953M | 6.4% |
| Other Primary Care Products | $654M | 4.4% |
| Padcev | $591M | 4.0% |
| Other Specialty Care | $579M | 3.9% |
| Xtandi | $444M | 3.0% |
| Oncology Biosimilars | $409M | 2.8% |
| Royalty | $396M | 2.7% |
| Other Oncology Products | $376M | 2.5% |
| Nurtec ODT Vydura | $353M | 2.4% |
| Lorbrena | $305M | 2.1% |
| Pfizer Centre One | $289M | 1.9% |
| Comirnaty | $232M | 1.6% |
| Inlyta | $214M | 1.4% |
| Sulperazon | $199M | 1.3% |
| Adcetris | $190M | 1.3% |
| Paxlovid EUA Labeled | $186M | 1.3% |
| Inflectra | $182M | 1.2% |
| Abrysvo | $180M | 1.2% |
| Xeljanz | $180M | 1.2% |
| Braftovi Mektovi | $174M | 1.2% |
| Zavicefta | $150M | 1.0% |
| Enbrel | $138M | 0.9% |
| Bosulif | $129M | 0.9% |
| Octagam | $122M | 0.8% |
| Tukysa | $122M | 0.8% |
| Zithromax Zmax | $112M | 0.8% |
| Orgovyx | $109M | 0.7% |
| Genotropin | $93M | 0.6% |
| FSMEIMMUN Tico Vac | $81M | 0.5% |
| Elrexfio | $80M | 0.5% |
| Cibinqo | $76M | 0.5% |
| Talzenna | $50M | 0.3% |
| Tivdak | $33M | 0.2% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $14.85B (-13%)
Oncology Biosimilars grew +55% year on yearPaxlovid EUA Labeled -62% year on year
Segment Latestquarter on quarteryear on year
- Eliquis$2.17B$2.17BQoQ +7.5%year on year +13%+7.5%+13%
- Prevnar Prevenar Family$1.69B$1.69BQoQ -3.0%year on year +1.8%-3.0%+1.8%
- Vyndaqel$1.60B$1.60BQoQ +0.69%year on year +7.8%+0.69%+7.8%
- Ibrance$1.01B$1.01BQoQ -4.6%year on year +3.2%-4.6%+3.2%
- All Other Hospital And Biosimilars$953.0M$953.0MQoQ -year on year +5.8%-+5.8%
- Other Primary Care Products$654.0M$654.0MQoQ -9.3%year on year +7.4%-9.3%+7.4%
- Padcev$591.0M$591.0MQoQ +27%year on year +39%+27%+39%
- Other Specialty Care$579.0M$579.0MQoQ +42%year on year +19%+42%+19%
- Xtandi$444.0M$444.0MQoQ -23%year on year -3.1%-23%-3.1%
- Oncology Biosimilars$409.0M$409.0MQoQ +30%year on year +55%+30%+55%
- Royalty$396.0M$396.0MQoQ -9.2%year on year +29%-9.2%+29%
- Other Oncology Products$376.0M$376.0MQoQ +38%year on year -0.27%+38%-0.27%
- Nurtec ODT Vydura$353.0M$353.0MQoQ -14%year on year +42%-14%+42%
- Lorbrena$305.0M$305.0MQoQ +14%year on year +37%+14%+37%
- Pfizer Centre One$289.0M$289.0MQoQ -16%year on year +5.9%-16%+5.9%
- Comirnaty$232.0M$232.0MQoQ -80%year on year -59%-80%-59%
- Inlyta$214.0M$214.0MQoQ -5.3%year on year -2.3%-5.3%-2.3%
- Sulperazon$199.0M$199.0MQoQ +29%year on year +21%+29%+21%
- Adcetris$190.0M$190.0MQoQ -12%year on year -13%-12%-13%
- Paxlovid EUA Labeled$186.0M$186.0MQoQ -85%year on year -62%-85%-62%
- Inflectra$182.0M$182.0MQoQ +5.2%year on year +19%+5.2%+19%
- Abrysvo$180.0M$180.0MQoQ -35%year on year +37%-35%+37%
- Xeljanz$180.0M$180.0MQoQ -42%year on year +41%-42%+41%
- Braftovi Mektovi$174.0M$174.0MQoQ -14%year on year +28%-14%+28%
- Zavicefta$150.0M$150.0MQoQ -5.1%year on year +11%-5.1%+11%
- Enbrel$138.0M$138.0MQoQ -10%year on year -1.4%-10%-1.4%
- Bosulif$129.0M$129.0MQoQ -14%year on year -15%-14%-15%
- Octagam$122.0M$122.0MQoQ +8.0%year on year +39%+8.0%+39%
- Tukysa$122.0M$122.0MQoQ +11%year on year +20%+11%+20%
- Zithromax Zmax$112.0M$112.0MQoQ +53%year on year -29%+53%-29%
- Orgovyx$109.0M$109.0MQoQ -2.7%year on year +43%-2.7%+43%
- Genotropin$93.0M$93.0MQoQ -27%year on year -2.1%-27%-2.1%
- FSMEIMMUN Tico Vac$81.0M$81.0MQoQ -19%year on year +29%-19%+29%
- Elrexfio$80.0M$80.0MQoQ -5.9%year on year +33%-5.9%+33%
- Cibinqo$76.0M$76.0MQoQ -3.8%year on year +31%-3.8%+31%
- Talzenna$50.0M$50.0MQoQ +6.4%year on year +25%+6.4%+25%
- Tivdak$33.0M$33.0MQoQ -11%year on year 0.00%-11%0.00%
- Aromasin--QoQ -year on year ---
- Cresemba--QoQ -year on year ---
- Other Hospital--QoQ -year on year ---
- Pfizer Ignite--QoQ -year on year ---
Drug Manufacturers - General
Ranks #14 of 16 by Smart Score